{
    "nctId": "NCT00437294",
    "briefTitle": "Enzastaurin in Combination of Capecitabine to Treat Breast Cancer",
    "officialTitle": "A Double-Blind, Randomized, Phase 2 Trial of Capecitabine Plus Enzastaurin Versus Capecitabine Plus Placebo in Patients With Metastatic or Recurrent Breast Cancer Previously Treated With an Anthracycline and a Taxane",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 86,
    "primaryOutcomeMeasure": "Progression Free Survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Have been diagnosed with metastatic or recurrent breast cancer.\n* Have been previously treated with both an anthracycline and a taxane.\n* Have not received more than two prior chemotherapy treatment programs.\n* Have stopped any antitumoral hormonal treatment before you enroll in this study.\n* Have a negative pregnancy blood test if menstruating or capable of becoming pregnant. You must use an approved birth control method during the study and for 3 months after stopping study treatment.\n\nExclusion Criteria:\n\n* Cannot follow the study procedures (for example, you cannot swallow tablets).\n* Are receiving another treatment for your cancer.\n* Have received another experimental drug in the last 4 weeks.\n* Have had serious heart disease within last 6 months.\n* Are pregnant or breast-feeding.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}